These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1040 related items for PubMed ID: 29284604

  • 21. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.
    Catapano AL, Pirillo A, Norata GD.
    Vasc Health Risk Manag; 2017; 13():343-351. PubMed ID: 28919772
    [Abstract] [Full Text] [Related]

  • 22. Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Durst R, Ibe UK, Shpitzen S, Schurr D, Eliav O, Futema M, Whittall R, Szalat A, Meiner V, Knobler H, Gavish D, Henkin Y, Ellis A, Rubinstein A, Harats D, Bitzur R, Hershkovitz B, Humphries SE, Leitersdorf E.
    Atherosclerosis; 2017 Feb; 257():55-63. PubMed ID: 28104544
    [Abstract] [Full Text] [Related]

  • 23. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
    Ohta N, Hori M, Takahashi A, Ogura M, Makino H, Tamanaha T, Fujiyama H, Miyamoto Y, Harada-Shiba M.
    J Clin Lipidol; 2016 Feb; 10(3):547-555.e5. PubMed ID: 27206942
    [Abstract] [Full Text] [Related]

  • 24. Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica.
    Alves AC, Alonso R, Diaz-Diaz JL, Medeiros AM, Jannes CE, Merchan A, Vasques-Cardenas NA, Cuevas A, Chacra AP, Krieger JE, Arroyo R, Arrieta F, Schreier L, Corral P, Bañares VG, Araujo MB, Bustos P, Asenjo S, Stoll M, Dell'Oca N, Reyes M, Ressia A, Campo R, Magaña-Torres MT, Metha R, Aguilar-Salinas CA, Ceballos-Macias JJ, Morales ÁJR, Mata P, Bourbon M, Santos RD.
    Arterioscler Thromb Vasc Biol; 2020 Oct; 40(10):2508-2515. PubMed ID: 32757650
    [Abstract] [Full Text] [Related]

  • 25. VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly.
    Croyal M, Blanchard V, Ouguerram K, Chétiveaux M, Cabioch L, Moyon T, Billon-Crossouard S, Aguesse A, Bernardeau K, Le May C, Flet L, Lambert G, Hadjadj S, Cariou B, Krempf M, Nobécourt-Dupuy E.
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):819-829. PubMed ID: 32078365
    [Abstract] [Full Text] [Related]

  • 26. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA, Elshourbagy NA, Mousa SA.
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [Abstract] [Full Text] [Related]

  • 27. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.
    Al-Hinai AT, Al-Abri A, Al-Dhuhli H, Al-Waili K, Al-Sabti H, Al-Yaarubi S, Al-Hashmi K, Banerjee Y, Al-Zakwani I, Al-Rasadi K.
    Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007
    [Abstract] [Full Text] [Related]

  • 28. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.
    Raal FJ, Santos RD.
    Atherosclerosis; 2012 Aug; 223(2):262-8. PubMed ID: 22398274
    [Abstract] [Full Text] [Related]

  • 29. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M.
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA, TESLA Investigators.
    Lancet; 2015 Jan 24; 385(9965):341-50. PubMed ID: 25282520
    [Abstract] [Full Text] [Related]

  • 31. Compound heterozygous familial hypercholesterolemia in a Chinese boy with a de novo and transmitted low-density lipoprotein receptor mutation.
    Ma Y, Gong Y, Garg A, Zhou H.
    J Clin Lipidol; 2018 Jan 24; 12(1):230-235.e6. PubMed ID: 29233637
    [Abstract] [Full Text] [Related]

  • 32. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
    Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ.
    JAMA Cardiol; 2017 Jun 01; 2(6):598-607. PubMed ID: 28291870
    [Abstract] [Full Text] [Related]

  • 33. Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe.
    Ruel I, Aljenedil S, Sadri I, de Varennes É, Hegele RA, Couture P, Bergeron J, Wanneh E, Baass A, Dufour R, Gaudet D, Brisson D, Brunham LR, Francis GA, Cermakova L, Brophy JM, Ryomoto A, Mancini GBJ, Genest J.
    Clin Chem; 2018 Feb 01; 64(2):355-362. PubMed ID: 29038147
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, Hamer A, Bridges I, Bartuli A, Bergeron J, Szamosi T, Santra S, Stefanutti C, Descamps OS, Greber-Platzer S, Luirink I, Kastelein JJP, Gaudet D, HAUSER-RCT Investigators.
    N Engl J Med; 2020 Oct 01; 383(14):1317-1327. PubMed ID: 32865373
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP, Worthy G, Gandra SR, Sattar N, Bray S, Cheng LI, Bridges I, Worth GM, Dent R, Forbes CA, Deshpande S, Ross J, Kleijnen J, Stroes ESG.
    J Am Heart Assoc; 2017 Oct 02; 6(10):. PubMed ID: 28971955
    [Abstract] [Full Text] [Related]

  • 38. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
    Scicali R, Di Pino A, Urbano F, Ferrara V, Marchisello S, Di Mauro S, Scamporrino A, Filippello A, Rabuazzo AM, Purrello F, Piro S.
    Nutr Metab Cardiovasc Dis; 2021 Mar 10; 31(3):869-879. PubMed ID: 33549441
    [Abstract] [Full Text] [Related]

  • 39. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, März W, Laufs U, Bölükbasi B, Steinhagen-Thiessen E, Scharnagl H, Kassner U.
    Vascul Pharmacol; 2019 May 10; 116():8-15. PubMed ID: 30910670
    [Abstract] [Full Text] [Related]

  • 40. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
    Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ.
    Circulation; 2013 Nov 05; 128(19):2113-20. PubMed ID: 24014831
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.